1차 출처 기록
중대신청 제출
Corcept, Cushing’s syndrome 으로 relacorilant NDA 재제출
Corcept가 FDA가 요청한 추가 분석을 완료한 후 Cushing’s syndrome 에 대한 relacorilant NDA를 재제출했습니다. 재제출은 6개월 심사 기간을 시작합니다. 제출 자료는 GRACE 및 GRADIENT 제3상 시험과 장기 연장 데이터로 지원됩니다.
핵심 사실
출처 발췌
EX-99.1 2 d159941dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome REDWOOD CITY , Calif., (June 17, 2026) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome. As requested by the FDA, the resubmi